These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 12354601

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Individualized treatment models based on blood supply characteristics in hepatocellular carcinoma using color Doppler hemodynamics.
    Si Q, Mu H, Yan G, Qian X, Xu C, Wang X, Tong W.
    Hepatogastroenterology; 2007 Mar; 54(74):334-41. PubMed ID: 17523269
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma.
    Maeda S, Shibata J, Fujiyama S, Tanaka M, Noumaru S, Sato K, Tomita K.
    Hepatogastroenterology; 2003 Mar; 50(51):809-13. PubMed ID: 12828090
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y, Liver Cancer Study Group of Japan.
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Transarterial chemoembolization combination therapy vs monotherapy in unresectable hepatocellular carcinoma: a meta-analysis.
    Li L, Tian J, Liu P, Wang X, Zhu Z.
    Tumori; 2016 Jun 02; 2016(3):301-10. PubMed ID: 27002950
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts.
    Tesdal IK, Wikström M, Flechtenmacher C, Filser T, Dueber C.
    Cardiovasc Intervent Radiol; 2006 Jun 02; 29(5):778-84. PubMed ID: 16779690
    [Abstract] [Full Text] [Related]

  • 18. Prospective comparison of transcatheter arterial chemoembolization with Lipiodol-epirubicin and Lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma.
    Sahara S, Kawai N, Sato M, Minamiguchi H, Nakai M, Takasaka I, Nakata K, Ikoma A, Sawa N, Sonomura T, Shirai S.
    Jpn J Radiol; 2010 Jun 02; 28(5):362-8. PubMed ID: 20585924
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection--a single-center analysis including 132 patients.
    Allgaier HP, Deibert P, Olschewski M, Spamer C, Blum U, Gerok W, Blum HE.
    Int J Cancer; 1998 Dec 18; 79(6):601-5. PubMed ID: 9842968
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.